Insider · CIK 0001544444

Arch Venture Partners VII, L.P.

CIK 0001544444 Name as filed on the most recent filing

Filed as Arch Venture Partners VII, L.P. (13)

28 transaction lines · from 13 filings · filed 2013-05-14 to 2025-10-29 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-10-27 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 4,999,977, acquired Open Form 4 filing 0001012975-25-000679
2023-09-19 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 25,500,000, acquired Open Form 4 filing 0000899243-23-019273
2020-12-22 P, Open-market purchase 908 Devices Inc.MASS 6,000,000, acquired Open Form 4 filing 0001104659-20-138752
2019-07-17 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 265,687, disposed Open Form 4 filing 0001012975-19-000489
2019-07-16 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 201,277, disposed Open Form 4 filing 0001012975-19-000489
2019-07-15 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 22,316, disposed Open Form 4 filing 0001012975-19-000489
2019-03-14 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 350,441, disposed Open Form 4 filing 0001012975-19-000242
2019-03-13 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 2 lines 666,565, disposed Open Form 4 filing 0001012975-19-000242
2019-03-12 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 295,374, disposed Open Form 4 filing 0001012975-19-000242
2019-03-11 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 291,366, disposed Open Form 4 filing 0001012975-19-000225
2019-03-08 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 585,270, disposed Open Form 4 filing 0001012975-19-000225
2019-03-07 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 242,013, disposed Open Form 4 filing 0001012975-19-000225
2018-11-02 P, Open-market purchase Twist Bioscience CorpTWST 2 lines 1,050,000, acquired Open Form 4 filing 0001012975-18-001198
2018-04-03 P, Open-market purchase Pulmatrix, Inc.PULM Not reported Open Form 4 filing 0000899243-18-009614
2016-07-06 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 5,000,000, acquired Open Form 4 filing 0001104659-16-131409
2016-05-23 S, Open-market sale Phaserx, Inc.PZRX 2 lines 6,801, disposed Open Form 4 filing 0001144204-16-104886
2016-05-23 P, Open-market purchase Phaserx, Inc.PZRX 5,000,000, acquired Open Form 4 filing 0001144204-16-104886
2015-06-16 P, Open-market purchase Pulmatrix, Inc.PULM 500,156, acquired Open Form 4 filing 0001144204-15-037762
2014-05-14 S, Open-market sale Receptos, Inc.RCPT 2 lines 238,334, disposed Open Form 4 filing 0001012975-14-000328
2014-05-13 S, Open-market sale Receptos, Inc.RCPT 4 lines 1,107,572, disposed Open Form 4 filing 0001012975-14-000328
2013-05-14 P, Open-market purchase Receptos, Inc.RCPT 3,982,790, acquired Open Form 4 filing 0001104659-13-041516

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. ARCH Venture Partners VII, L.P., insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001544444

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.